SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Mymetics Corporation (MYMX)

MYMX RSS Feed
Add MYMX Price Alert      Hide Sticky   Hide Intro
Moderator: HokieHead, corpus
Search This Board: 
Last Post: 2/14/2017 10:21:30 PM - Followers: 18 - Board type: Free - Posts Today: 0

                    MyMetics                     

http://www.mymetics.com/

 

Mymetics Corporation is US registered biotechnology company with its main offices in Switzerland and the Netherlands. Focused on developing next generation preventative vaccines for infectious diseases. Mymetics core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins in combination with rationally designed antigens and membrane proteins.

Mymetics currently has 5 vaccines in its pipeline:
HIV/AIDS
Intranasal Influenza
RSV
Herpes Simplex
Malaria

 


Current Share Structure:



Oustanding Shares: 303.7 million (11/2016 & no change since 2012)
Floating Shares: 76 million  (12/2016)

Current Market Cap (12/7/16): $5.0 million
Enterprise Value: $51.9 million*

*Enterprise value can be thought of as the theoretical takeover price if the company were to bought. In the event of such a buyout, an acquirer would generally have to take on the company's debt, but would pocket its cash for itself. EV differs significantly from simple market capitalization in several ways, and many consider it to be a more accurate representation of a firm's value.


RECENT NEWS WITH SANOFI:

Mymetics Starts Research Project with Sanofi for Influenza Vaccines

Dec 01, 2016
OTC Disclosure & News Service

EPALINGES, Switzerland, Dec. 1, 2016

EPALINGES, Switzerland, Dec. 1, 2016 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (NYSE: SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics' proprietary virosome technology platform in pre-clinical settings. If this project is successful it could result in a further and more extensive collaboration between the two companies.

"We are very excited to start this initial collaboration project with Sanofi, a world leader in the vaccine industry," said Ronald Kempers, CEO of Mymetics. "We look forward to show that our proprietary virosome technology and more than 30 years of virosome vaccines expertise can make a valuable difference in improving the effectiveness and cost competitiveness of influenza vaccines."

About Mymetics
Mymetics Corp. (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious diseases. It currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya, Herpes Simplex Virus and the RSV vaccine. HIV, malaria and intra-nasal influenza vaccines have successfully finished Phase 1 clinical trials, while the others are in the pre-clinical phase.

Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Mymetics' vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, in combination with humoral and cellular immune responses as a second-line defense, which can be essential for the development of an effective vaccine.

Mymetics' unique approach is being validated through partnerships with leading pharmaceutical or research organizations, including projects with PATH-MVI and the Bill and Melinda Gates Foundation.

For further information, please visit www.mymetics.com.

 




 

OTC Disclosure & News Service

Release Date Title Type
Dec 1, 2016 Mymetics Starts Research Project with Sanofi for Influenza Vaccines Press Release
Sep 19, 2016 Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development Press Release
Apr 11, 2016 Mymetics' HIV Vaccine Candidate Confirms Promise in Preclinical Study With the Texas Biomedical Research Institute Press Release
Apr 5, 2016 Mymetics Announces Successful Preclinical Results With Malaria Transmission-Blocking Vaccine Candidate Press Release
Jan 28, 2016 Mymetics Announces Discontinuation of the RSV Collaborative Project Press Release
Apr 20, 2015 Mymetics' led consortium awarded Euro 8.4 million to develop thermo stable and cold chain independent vaccines Press Release
Jan 2, 2015 OTC Markets Group Welcomes Newly Verified OTCQB Companies – Jan. 2 Announcement
Nov 18, 2014 Mymetics Announces New Collaboration to Advance the Development of an Innovative Malaria Vaccine Candidate Press Release
Sep 29, 2014 Mymetics' Promising HIV Vaccine Candidate Obtains Funding to Begin Study at Texas Biomedical Research Institute Press Release

 





WEEKLY CHART:


  •  
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MYMX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
MYMX News: Confidential Treatment Order (ct Order) 02/14/2017 03:25:02 PM
MYMX News: Amended Current Report Filing (8-k/a) 01/26/2017 09:15:15 AM
MYMX News: Current Report Filing (8-k) 12/01/2016 08:13:32 AM
MYMX News: Quarterly Report (10-q) 11/14/2016 02:43:10 PM
PostSubject
#641  Sticky Note Mymetics Starts Research Project with Sanofi for Influenza Vaccines HokieHead 12/02/16 04:58:35 PM
#798   Funny :0 not to mention the initial corpus 02/14/17 10:21:30 PM
#797   "Doesn't really mean much?" Likely, near term. corpus 02/14/17 10:12:08 PM
#796   This clearly means that this will be huge, tyfoidhana 02/14/17 07:19:50 PM
#795   Doesn't really mean much? What's your take. TIA.. HokieHead 02/14/17 05:01:43 PM
#794   Confidential Treatment Order on 8-K/A SEC filing granted corpus 02/14/17 04:42:53 PM
#793   Is it possible that the comparator vaccine under corpus 02/11/17 12:25:55 PM
#792   Dr. Thomas Monath #2 as well. I remember corpus 02/10/17 03:55:42 PM
#791   From that site; Harry Wickey 02/10/17 01:05:02 PM
#790   Malaria Vaccine Market - Global industry insights, Trends, corpus 02/08/17 11:49:55 PM
#789   "In 2017 and beyond we will continue to corpus 02/08/17 01:20:34 PM
#787   The more I read the original agreement from tyfoidhana 01/26/17 08:23:54 PM
#786   I feel ya I haven't been sitting on tyfoidhana 01/26/17 05:55:49 PM
#785   Mymetics >>> too secretive? But I'll take it corpus 01/26/17 02:29:39 PM
#784   I believe our current contract with Sanofi expires tyfoidhana 01/24/17 04:05:39 AM
#783   Found another one; Mymetics and partner Sanofi Pasteur corpus 01/23/17 09:28:18 PM
#782   I see it comes in the middle of tyfoidhana 01/23/17 08:26:30 PM
#781   Found out Mymetics and partner Sanofi Pasteur are corpus 01/23/17 04:52:10 PM
#779   Trump! Trump! Trump! tyfoidhana 01/20/17 10:46:02 PM
#777   MYMX Partnered with NYSE Sanofi alone is worth .20 KEEMAJO 01/06/17 05:20:05 PM
#776   Mymx popping higher ronpopeil 01/06/17 03:50:35 PM
#773   MYMX HUGE>"If this project is successful it could KEEMAJO 01/06/17 09:29:10 AM
#772   MYMX has agreed on a research project with KEEMAJO 01/06/17 09:28:18 AM
#771   MYMX chart looks set to launch-A Beauty KEEMAJO 01/04/17 06:12:31 AM
#770   Biggest names in vaccine science make news today. remind2 01/03/17 03:35:46 PM
#769   Large block went form Ask to Bid??? Harry Wickey 01/03/17 02:54:03 PM
#768   MYMX stupid cheap, should be .20 KEEMAJO 12/30/16 11:36:57 AM
#767   123 shares, really? Lol KEEMAJO 12/29/16 11:54:50 AM
#766   MYMX worth .20 plus... babies afraid of real value!? KEEMAJO 12/28/16 06:53:19 PM
#765   MYMX sooooo close to Breaking out! KEEMAJO 12/27/16 03:27:44 PM
#764   MYMX has a a lot of great things KEEMAJO 12/26/16 02:58:36 PM
#763   https://drive.google.com/file/d/0B9gihiVeZywjSHgzRGR4ckxKb0k/view?usp=sharing MYMETIC corpus 12/26/16 01:33:08 PM
#762   Merry Christmas Everyone! corpus 12/25/16 10:40:40 PM
#761   Few be it that have patience for this tyfoidhana 12/23/16 07:13:39 PM
#760   I'm buying! Harry Wickey 12/23/16 01:58:14 PM
#759   I guess everyone sold ronpopeil 12/23/16 01:30:15 PM
#758   "They" may let it run today. At DumpOnUrPump 12/19/16 09:33:58 AM
#757   Volume got aids for sure 514 12/15/16 06:31:25 PM
#756   hey bro, Aids stock here lol IN The Mouth Of Madness 12/15/16 04:14:34 PM
#755   Major vaccine figure in the news. remind2 12/14/16 11:59:23 PM
#754   This is getting loaded no doubt. Support well 514 12/11/16 11:37:40 AM
#753   Finally some buying pressure on the ask EOD. DumpOnUrPump 12/09/16 03:52:54 PM
#752   <MYMX> HookieHead, I changed the float in the corpus 12/09/16 01:42:43 PM
#751   <MYMX> Yes. No changes made from the previous percentage. corpus 12/09/16 01:11:20 PM
#750   <MYMX> Shares seems tight. Hopefully in stronger hands now. corpus 12/09/16 01:05:41 PM
#749   MYMX ready for take-off... $MYMX pennyfinder 12/09/16 12:58:52 PM
#748   300M outstanding 25% of public float, which means pennyfinder 12/09/16 12:57:45 PM
#747   Sept.2015 >>> Start of exploratory study of two corpus 12/09/16 12:01:29 PM
#746   <<< Mymetics' Overview >>> ***UPDATED*** corpus 12/09/16 11:55:34 AM
#745   Perhaps...time will tell. retireat40 12/07/16 05:34:29 PM
#744   Congratulations! Good move there. corpus 12/07/16 05:11:05 PM
PostSubject